Clinical trials: Human Immunodeficiency Virus I Infection
Sarcoma, Kaposi, HIV Infections
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00000725
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
Cabotegravir is being developed for the treatment of human immunodeficiency virus (HIV) 1 infection. Specifically, it is being developed as a component of a 2-drug maintenance regimen (post-induction of viral suppression) that…
- Trial name
- NCT02799264
- Testing
- Cabotegravir 30 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who…
- Trial name
- NCT00757250
- Testing
- Angiotensin 1-7
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- US Biotest, Inc.
Tuberculosis
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
Phase I, randomized, double blinded, Placebo-controlled, immunogenicity and dose-range finding study of AERAS-404 in Bacille Calmette-Guerin (BCG) healthy adult male and sterile females.
- Trial name
- NCT02066428
- Testing
- AERAS-404
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Aeras
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV HealthcareLLC.
- Trial name
- NCT01209065
- Testing
- GSK1349572, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Toxoplasmosis, Cerebral, HIV Infections
A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute therapy for toxoplasmic encephalitis in AIDS patients.
- Trial name
- NCT00000966
- Testing
- Azithromycin, Pyrimethamine, Leucovorin calcium
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
HIV-1 Infection
Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults
This is a double blind, randomized, placebo-controlled, parallel design, study in which 24 HIV-infected participants with durable viral suppression will be randomly assigned to receive vaccination with MVA.tHIVconsv3 (M3)…
- Trial name
- M&M (NCT03844386)
- Testing
- MVA.tHIVconsv3, MVA.tHIVconsv4
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
To assess the steady state pharmacokinetic features, tolerance, and safety of orally administered 1592U89, given alone or in combination with other antiretroviral medications, in HIV infected infants and children.
- Trial name
- NCT00000865
- Testing
- Abacavir sulfate, Lamivudine, Stavudine
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, HIV Infection
DCVax Plus Poly ICLC in Healthy Volunteers
DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection.
- Conditions
- HIV-1 Infection, HIV Infection, Healthy Volunteers
- Trial name
- NCT01127464
- Testing
- DCVax-001, Poly-ICLC
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
The purpose of this study is to determine the tolerance and effectiveness of rhIL-12 in HIV-positive patients with CD4 cell counts less than 50 cells/mm3 versus 300-500 cells/mm3.
- Trial name
- NCT00000857
- Testing
- Interleukin-12
- Where
- 16 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Papilloma Virus, Human Immunodeficiency Virus
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions.
- Conditions
- Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
- Trial name
- NCT06233331
- Testing
- Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
HIV Infections
Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate…
- Trial name
- NCT00002012
- Testing
- Interferon alfa-n3
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Interferon Sciences
Human Immunodeficiency Virus-Type 1
A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients
The purpose of this study is to assess the safety and effectiveness of darunavir for the treatment human immunodeficiency virus-type I (HIV-1) infection among Filipino adults.
- Trial name
- NCT01726348
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
HIV Infections
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
The purpose of this study is to assess the safety of GX-12 gene therapy combined with HAART in the HIV-1 infected patients and to investigate the efficacy with the value of plasma viral load and with CD4 counts and HIV-1 specific…
- Trial name
- NCT00517569
- Testing
- GX-12, HAART
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Genexine, Inc.
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection
ICVAX as a HIV Therapeutic DNA Vaccine
The clinical trial is a dose-escalation, randomized, double-blind, placebo-controlled phase I study at a single center to evaluate the safety, tolerability and immunogenicity of HIV Therapeutic DNA Vaccine, ICVAX, in clinically…
- Trial name
- NCT06253533
- Testing
- ICVAX
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Immuno Cure Holding (HK) Limited
HIV I Infection, HIV-2 Infection
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer
- Trial name
- HIV-EU-11-18 (NCT04971343)
- Testing
- Access HIV_blood donor, Access HIV_Hospitalized patient, Access HIV_known HIV-1 antibody positives
- Where
- 6 sites in France
- Volunteers
- 8,650 people
- Sponsor
- Beckman Coulter, Inc.
HIV I Infection
Leveraging Family-Based Assets for Black MSM In House Ball Communities
Despite the advent of highly effective prevention tools such as HIV pre-exposure prophylaxis (PrEP), Black men who have sex with men (MSM) continue to have the highest incidence of new HIV diagnoses in the US but are least likely…
- Trial name
- NCT05071378
- Testing
- Our Family, Our Voices
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- State University of New York - Downstate Medical Center
HIV Infections
Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
The purpose of this study was to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), in adults infected with HIV who were receiving antiretroviral therapy…
- Trial name
- NCT02411539
- Testing
- VRC01
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C.
- Trial name
- NCT00001035
- Testing
- Interferon alfa-2b, Zidovudine, Zalcitabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)